Chemotherapy-Induced Alopecia: Overview and Methodology for Characterizing Hair Changes and Regrowth
- 3 September 2010
- book chapter
- Published by Springer Nature
- p. 381-386
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study groupSupportive Care in Cancer, 2010
- Cutaneous side-effects of kinase inhibitors and blocking antibodiesThe Lancet Oncology, 2005
- Prevention of chemotherapy-induced hair loss by scalp coolingAnnals of Oncology, 2005
- CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatmentSeminars in Radiation Oncology, 2003
- Epidermal Growth Factor Receptor Inhibition Induces TrichomegalyActa Oncologica, 2003
- Relationship between irreversible alopecia and exposure to cyclophosphamide, thiotepa and carboplatin (CTC) in high-dose chemotherapyBone Marrow Transplantation, 2002
- Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptorBritish Journal of Dermatology, 2002
- Alopecia areata investigational assessment guidelines*Journal of the American Academy of Dermatology, 1999
- A randomized trial of minoxidil in chemotherapy-induced alopeciaJournal of the American Academy of Dermatology, 1996
- Protection from chemotherapy‐induced alopeciaMedical and Pediatric Oncology, 1991